Guided Therapeutics (GTHP) Gross Margin (2012 - 2025)
Guided Therapeutics (GTHP) posted Gross Margin of 77.63% for Q4 2025, up 33.08% sequentially from 58.33% in Q3 2025, and up 27763.0% YoY from N/an in Q4 2024.
Guided Therapeutics (GTHP) Gross Margin (2012 - 2025) Analysis & Trends
Guided Therapeutics has reported Gross Margin for 14 years, with the latest figure at 77.63% in Q4 2025.
- Quarterly Gross Margin rose 27763.0% year-over-year to 77.63% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 74.58% (up 4600.0% YoY) and the FY2025 annual result came in at 74.45%, up 4587.0% from the prior year.
- Gross Margin climbed to 77.63% in Q4 2025 per GTHP's latest filing, from 58.33% in the prior quarter.
- Over five years, Gross Margin peaked at 100.0% in Q2 2021 and troughed at 200.0% in Q4 2024.
- A 5-year average of 36.54% and a median of 67.09% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2021 and 2025: Gross Margin plunged 27167 bps in 2021, then surged 27763 bps in 2025.
- Over 5 years, Gross Margin stood at 68.33% in 2021, then jumped by 46 bps to 100.0% in 2022, then slumped by 50 bps to 50.0% in 2023, then tumbled by 500 bps to 200.0% in 2024, then surged by 139 bps to 77.63% in 2025.
- According to Business Quant data, Gross Margin over the past three periods registered 77.63%, 58.33%, and 67.52% for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.70 Bn | 193.10 Bn | 7.27 Bn | 57.71% |
| 2 | Stryker | 125.85 Bn | 122.37 Bn | 4.50 Bn | 68.27% |
| 3 | Medtronic | 118.44 Bn | 109.22 Bn | 6.41 Bn | 65.35% |
| 4 | Boston Scientific | 72.64 Bn | 72.10 Bn | 3.85 Bn | 70.71% |
| 5 | Edwards Lifesciences | 51.94 Bn | 47.69 Bn | 1.35 Bn | 77.46% |
| 6 | Dexcom | 34.48 Bn | 32.53 Bn | 830.00 Mn | 63.44% |
| 7 | GE HealthCare Technologies | 33.60 Bn | 31.49 Bn | 2.18 Bn | 41.17% |
| 8 | Koninklijke Philips | 26.30 Bn | 22.98 Bn | 4.55 Bn | 47.38% |
| 9 | Steris | 23.00 Bn | 22.52 Bn | 684.20 Mn | 45.84% |
| 10 | Guided Therapeutics | 26.06 Mn | 26.05 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77.63% |
| Sep 30, 2025 | 58.33% |
| Jun 30, 2025 | 67.52% |
| Dec 31, 2024 | -200.00% |
| Mar 31, 2024 | 66.67% |
| Dec 31, 2023 | 50.00% |
| Jun 30, 2023 | 25.00% |
| Mar 31, 2023 | 59.09% |
| Sep 30, 2022 | 100.00% |
| Jun 30, 2022 | 80.00% |
| Mar 31, 2022 | 80.00% |
| Dec 31, 2021 | 68.33% |
| Sep 30, 2021 | -121.05% |
| Jun 30, 2021 | 100.00% |
| Dec 31, 2020 | 340.00% |
| Sep 30, 2020 | 84.42% |
| Dec 31, 2019 | 75.00% |
| Sep 30, 2019 | 100.00% |
| Jun 30, 2019 | -6,400.00% |
| Mar 31, 2019 | 94.44% |